Market research

AIDX 20/20 Biolabs, Inc. Common Stock

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

Market cap: 7M
P/E ratio: Not available
Analyst target: 5
Dividend yield: Not available
Beta: -0.42

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Medical Devices
ISIN: US90138K1016
Market cap: 7M
P/E ratio: Not available
Analyst target: 5
Dividend yield: Not available
Beta: -0.42

About

About 20/20 Biolabs, Inc. Common Stock

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about AIDX.

AIDX 20/20 Biolabs, Inc. Common Stock

Price & volume

Company facts

About 20/20 Biolabs, Inc. Common Stock

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet